Log in to your Inderes Free account to see all free content on this page.
Create account

Lytix Biopharma

Less than 1K followers

LYTIX

Euronext Growth Oslo

Biotechnology & Pharmaceuticals

Health Care

Lytix Biopharma is a clinical-stage biotechnology company developing cancer immunotherapies. The company's technology is based on research into antimicrobial peptides, a defense against pathogens. Lytix Biopharma's lead product, LTX-315, is an oncolytic peptide with the aim of personalizing immunotherapy. The company conducts its research and operations in Oslo, Norway.

Read more
Market cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
27.8.
2026

Interim report Q2'26

11.11.
2026

Interim report Q3'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.